Results 221 to 230 of about 7,329,727 (241)

A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD

Expert Review of Clinical Pharmacology, 2022
Single inhaler triple therapy (SITT) with an inhaled corticosteroid, a long-acting β2-agonist, and a long-acting muscarinic antagonist is an effective and attractive therapeutic option codified in the recommendations of guidelines and treatment strategies for the management of COPD.The preclinical and clinical development in COPD of fluticasone furoate
Paola Rogliani, Josuel Ora, Maria Gabriella Matera   +2 more
exaly   +5 more sources

Efficacy and Safety of Single Inhaler Triple Therapy Versus Separate Triple Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

Clinical Therapeutics, 2022
This study aimed to compare the efficacy and safety of single inhaler triple therapy and separate triple therapy in the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov databases were searched, and the search date was set from database ...
Liansheng, Zhang, Xiaoqing, Wang, Ye, Zhang, Wenyu, Chen   +3 more
exaly   +3 more sources

Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD

Respiratory Care, 2023
BACKGROUND: COPD is characterized by progressive and irreversible air flow limitations. Single-inhaler therapies (SITTs) incorporating an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β 2 -agonist have been shown ...
Kengo, Ohtsuka, Naoko, Harada, Atsuo, Horiuchi, Shintaro, Umemoto, Ryo, Kurabatashi, Akie, Yui, Hiroyuki, Yamamura, Yoko, Shinka, Naoki, Miyao   +8 more
openaire   +2 more sources

Single inhaler triple therapy for COPD

Drug and Therapeutics Bulletin, 2017
The European Medicines Agency (EMA) has granted marketing authorisation for a pressurised metered dose inhaler (pMDI) containing beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium bromide (Trimbow – Chiesi Pharmaceuticals) for the treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated with
openaire   +2 more sources

Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD

Ethics and Economics, 2018
Background: IMPACT (InforMing the PAthway of COPD Treatment, NCT02164513), showed superior exacerbation reduction and lung function improvement with single inhaler, once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/22μg vs once-daily FF/VI 100/22μg, for patients with moderate/severe COPD.
Alan A Martin, Dhvani Shah, Emma C Goodall, Melanie Schroeder, Nancy Risebrough, Kerigo Ndirangu, Afisi S Ismaila   +6 more
openaire   +1 more source

Triple therapy in a single inhaler: a new option for uncontrolled asthma

The Lancet, 2019
J Mark, FitzGerald, Mohsen, Sadatsafavi
openaire   +2 more sources

Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study

Respiratory Medicine, 2022
Sean MacKnight, Mei Sheng Duh, Willy Wynant   +2 more
exaly  

Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain

Chest, 2022
Antoni Sicras-Mainar, Bernardino Alcazar Navarrete, Joaquín Sánchez-Covisa   +2 more
exaly  

Single-inhaler triple therapy for prevention of COPD exacerbations

Drug and Therapeutics Bulletin, 2017
openaire   +2 more sources

Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β2-agonist) in asthma patients: a narrative review

Journal of Asthma, 2023

exaly